hlx48
Advanced/Metastatic Solid Tumors
Shanghai Henlius BiotechPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Advanced/Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ADG 106 Adagene Inc | Phase 1/2 | B |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
Muzastotug Adagene Inc | Phase 1/2 | CCC |
immunoglobulin G1- kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody (Firastotug) Adagene Inc | Phase 1 | CCC |
Mcla-158 Merus B.V. | Phase 1/2 | CC |
View all 33 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →